In addition to targeted drugs, treatment of advanced HER2-positive breast cancer patients mainly involves a blend of endocrine, chemotherapy, and immunotherapy; however, chemotherapy or endocrine resistance is inevitable treatment [3–6]. This evidence concerns the gene ERBB2 and breast carcinoma.